Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transdermal Nicotine for Response Inhibition in Schizophrenia
NCT03838484Terminated
- Sponsor
- Vanderbilt University Medical Center
- Start
- May 2019
- Primary completion
- Feb 2020
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of nicotine patch in schizophrenia (4 arms), sponsored by Vanderbilt University Medical Center. Primary endpoints: False Alarm Error Rate at Week 2, Omission Error Rate at Week 2 and 2 more. Started May 2019; status: terminated.
02
Drugs
nicotine patch
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03838484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03838484.